Clinical trials: Bladder
Cholecystitis
Subserosal Laparoscopic Cholecystectomy
The aim is to study the safety and efficacy of subserosal laparoscopic cholecystectomy .
- Trial name
- NCT05770128
- Testing
- laparoscope
- Volunteers
- 65 people
- Sponsor
- Assiut University
Non-muscle-invasive Bladder Cancer
Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer
Bacillus Calmette-Guerin (BCG) is the standard of care for high-risk patients with non-muscle invasive bladder cancer (NMIBC) after transurethral tumor resection.
- Trial name
- NCT05671900
- Testing
- Gemcitabine 1000 mg, Docetaxel 37.5g
- Where
- Croatia
- Volunteers
- 70 people
- Sponsor
- Clinical Hospital Centre Zagreb
Over Active Bladder, Urinary Incontinence (UI)
Electroacupuncture as a Treatment for Refractory Overactive Bladder
This study is a single-site feasibility randomised controlled trial evaluating the feasibility and acceptability of electroacupuncture (EA), and percutaneous tibial nerve stimulation (PTNS), in women with refractory overactive…
- Conditions
- Over Active Bladder, Urinary Incontinence (UI), Nocturia
- Trial name
- EAOAB (NCT07124390)
- Testing
- Name: Electroacupuncture (EA) Type: Device-based acupuncture therapy, Neuromodulation therapy
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
Radical Cystectomy, Urothelial Carcinoma
Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma
A multicenter, open, single arm, phase II clinical trial was designed for myometrial invasive bladder cancer to evaluate the efficacy and safety of RC48-ADC combined with gemcitabine in preoperative neoadjuvant treatment of MIBC…
- Trial name
- NCT05723991
- Testing
- Disitamab Vedotin and Gemcitabine
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Chunguang yang (101937)
NMIBC
A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
A Phase I-II Study of Novel Oncolytic Virus VG161 via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (VG-INFUSE Trial) Background: The treatment of recurrent/refractory non-muscle-invasive…
- Trial name
- VG-INFUSE Tria (NCT07505615)
- Testing
- VG161 via Intravesical Instillation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ding-Wei Ye
Gall Stone, Gallbladder Inflammation
Benchmarks in Elective Laparoscopic Cholecystectomy
The aim of this observational cohort study is to define peri- and postoperative reference values for elective laparoscopic cholecystectomy, using the achievable benchmarks of care methodology (ABC™).
- Conditions
- Gall Stone, Gallbladder Inflammation, Gall Bladder Pain, Gallstone
- Trial name
- NCT06692517
- Testing
- Laparoscopic cholecystectomy
- Volunteers
- 60,000 people
- Sponsor
- Region Östergötland
Spinal Cord Injuries
Transcutaneous Tibial Nerve Stimulation for Spinal Cord Injury Neurogenic Bladder
The purpose of this study is to determine if electric stimulation to the leg, called transcutaneous tibial nerve stimulation (TTNS), can improve bladder outcomes in acute spinal cord injury.
- Trial name
- TTNS1yr (NCT04350359)
- Testing
- Variable-dose TTNS Protocol 5 x week, Fixed-dose TTNS Protocol, Variable-dose TTNS Protocol 2 x week
- Where
- 2 sites in United States
- Volunteers
- 111 people
- Sponsor
- The University of Texas Health Science Center, Houston
Urothelial Carcinoma, Bladder Cancer
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
The purpose of this trial is to determine the benefit of the combination of nab-paclitaxel plus gemcitabine given for 6 cycles, followed by maintenance nab-paclitaxel alone, in patients with cisplatin-ineligible or…
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Transitional Cell Carcinoma
- Trial name
- NCT02887248
- Testing
- nab-paclitaxel, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- SCRI Development Innovations, LLC
Urothelial Carcinoma
A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
A multicenter ambispective (retrospective and prospective) non-interventional study of patients with locally advanced or metastatic urothelial carcinoma (adv/mUC) treated with avelumab in France, not impacting the treatment…
- Trial name
- AVENANCE (NCT04822350)
- Testing
- Avelumab
- Where
- 81 sites in France
- Volunteers
- 596 people
- Sponsor
- Pfizer
Bladder Cancer
Combination Chemotherapy in Treating Patients With Bladder Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00014534
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- 285 sites in United States
- Volunteers
- 42 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Urinary Bladder, Overactive
Comparison of the Efficacy of Perineal and Intravaginal Electrical Stimulation in Women With Idiopathic Overactive Bladder
The investigators conducted a prospective, randomized double-blind, placebo-controlled study based on a placebo technique to evaluate the efficacy of IVES vs perineal ES in women with idiopathic OAB.
- Trial name
- NCT07366918
- Testing
- Intravaginal ES, BT, Perineal ES
- Where
- Turkey (Türkiye)
- Volunteers
- 63 people
- Sponsor
- Pamukkale University
Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A
Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
The purpose of this study is to determine if TAR-200, an investigational drug delivery system, in combination with nivolumab is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) who are scheduled for…
- Conditions
- Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A, Bladder Cancer TNM Staging Primary Tumor (T) T2B, Bladder Cancer TNM Staging Primary Tumor (T) T3
- Trial name
- NCT03518320
- Testing
- Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200, Nivolumab Injection [Opdivo]
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Taris Biomedical LLC
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other…
- Conditions
- Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma
- Trial name
- NCT03866382
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 582 sites in United States, Puerto Rico
- Volunteers
- 314 people
- Sponsor
- National Cancer Institute (NCI)
Lower Urinary Tract Symptoms
Symptoms of Lower Urinary Tract Dysfunction Protocol 2/Recall Study
The purpose of this study is to advance the understanding of people who experience urinary and bladder problems. The investigators are interested in learning about people's experiences with urinary symptoms and how these symptoms…
- Trial name
- NCT03808038
- Testing
- None- Observational Study
- Where
- 6 sites in United States
- Volunteers
- 515 people
- Sponsor
- Arbor Research Collaborative for Health
Urinary Bladder, Neurogenic
Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients
The proposed study is a randomized, double blind placebo controlled multicenter study to determine the effectiveness of mirabegron in the treatment of neurogenic bladder dysfunction.
- Trial name
- NCT02044510
- Testing
- Mirabegron
- Where
- 5 sites in Canada
- Volunteers
- 32 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Bladder Perforation, Retropubic Midurethral Sling
Retropubic Hydrodissection and Trocar-induced Bladder Perforation During Retropubic Midurethral Slings
Retropubic midurethral slings are a common and effective treatment for stress urine incontinence. The trocar that is attached to the mesh material can hit the bladder which is called a perforation.
- Conditions
- Bladder Perforation, Retropubic Midurethral Sling, Retropubic Hydrodissection
- Trial name
- NCT07208682
- Testing
- retropubic hydrodissection
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Overactive Bladder
Overactive Bladder (OAB) Voiding Diary and Urodynamics Correlation Study
This is a prospective cohort study study with the primary aim of identifying the strongest correlating parameters between voiding diaries and UDS studies most predictive for each type of urologic condition.
- Trial name
- NCT03473782
- Testing
- Voiding Diary, Urodynamics Correlation Study
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- NYU Langone Health
Spinal Cord Injuries
Spinal Cord Stimulation for Autonomic Recovery in Inpatient Rehabilitation After Acute SCI
This study is a randomized, single-blind, two-arm sham-controlled clinical trial to evaluate the safety and efficacy of transcutaneous spinal cord stimulation (tSCS) over the lower thoracic and upper lumbar spinal cord segments…
- Trial name
- NCT06540859
- Testing
- Transcutaneous Spinal Cord Stimulation
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Washington
Non-muscle Invasive Bladder Cancer
A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer
Prior to performing any study specific procedure (including screening procedures to determine eligibility), a signed consent form will be obtained for each subject.
- Trial name
- Hydeal Cyst (NCT06245603)
- Testing
- Hydeal Cyst®
- Where
- 9 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Bladder Cancer
Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer
RATIONALE: Minimal-access surgery uses a smaller opening in the body to remove the tumor than is used in standard surgery. It is not yet known whether minimal-access surgery to remove the bladder is more effective than standard…
- Trial name
- NCT01196403
- Testing
- questionnaire administration, quality-of-life assessment, robot-assisted laparoscopic surgery
- Where
- 4 sites in United Kingdom
- Volunteers
- 92 people
- Sponsor
- Wales Cancer Trials Unit
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.